Accurate diagnosis and proper monitoring of cancer patients remain important obstacles for successfulcancer treatment. The search for cancer biomarkers can aid in more accurate prediction of clinical outcomeand may also reveal novel predictive factors and therapeutic targets. One such prognostic marker seems to beFOXA1. Many studies have shown that FOXA1 is strongly expressed in a vast majority of cancers, includingbreast cancer, in which high expression is associated with a good prognosis. In this review, we summarize the roleof this transcription factor in the development and prognosis of breast cancer in the hope of providing insightsinto utility of FOXA1 as a novel biomarker.